Argenx SE stock (NL0010832176): FDA expands Vyvgart approval for all gMG patients

Argenx SE announced on May 8, 2026, that the U.S. Food and Drug Administration approved label expansions for its Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), making them the first and only approved treatments for all adult patients with generalized myasthenia gravis (gMG), including those who are anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative, argenx press release as of May 8, 2026.

This regulatory milestone broadens access to Argenx's lead therapy in the U.S., a key market for the Nasdaq-listed biotech. The approval follows positive clinical data demonstrating efficacy across serotypes. Argenx SE also held its Q1 2026 earnings call on May 7, 2026, providing updates on financials and pipeline progress, according to MarketScreener as of May 8, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Argenx SE: core business model

Argenx SE is a global immunology company focused on developing antibody-based therapies for severe autoimmune diseases. Through its Immunology Innovation Program (IIP), it partners with academic researchers to advance novel treatments. The company's lead product, Vyvgart, is the first approved neonatal Fc receptor (FcRn) blocker, targeting antibody-mediated autoimmune conditions, MarketScreener company profile as of May 8, 2026.

Argenx SE commercializes Vyvgart and is expanding its application across multiple indications. The firm is also advancing earlier-stage experimental medicines within its therapeutic franchises. Listed on Nasdaq (ARGX) and Euronext Bruxelles, it offers U.S. investors exposure to biotech innovation with significant U.S. market reliance.

Main revenue and product drivers for Argenx SE

Vyvgart drives the majority of Argenx SE's revenue, primarily from sales treating gMG in the U.S. The recent FDA label expansion significantly enlarges the addressable patient population by including all serotypes. Vyvgart Hytrulo, a subcutaneous version, enhances patient convenience and supports uptake.

Prior to this approval, Vyvgart was approved for broader gMG use, but the expansion to seronegative patients addresses an unmet need. Argenx SE reported Q1 2026 results on May 7, 2026, with details on Vyvgart sales growth available in its earnings materials.

Industry trends and competitive position

The autoimmune disease market is growing due to increasing prevalence and demand for targeted therapies. FcRn inhibitors like Vyvgart represent a novel mechanism, differentiating Argenx SE from traditional immunosuppressants. Competitors include other biotechs developing similar modalities, but Argenx holds first-mover advantage in gMG.

U.S. approvals are pivotal for revenue acceleration, given Medicare and commercial reimbursement dynamics. Argenx SE's pipeline in additional autoimmune indications positions it for multi-product growth.

Why Argenx SE matters for US investors

As a Nasdaq-listed company with primary revenue from U.S. Vyvgart sales, Argenx SE provides direct exposure to the lucrative American biotech sector. FDA decisions like the May 8 expansion directly impact its growth trajectory and valuation for U.S. retail investors tracking immunology plays.

Conclusion

The FDA's label expansion for Vyvgart and Vyvgart Hytrulo marks a key advancement for Argenx SE, broadening its market in gMG and underscoring its leadership in FcRn inhibition. Coupled with recent earnings and analyst coverage, the company continues to execute on its immunology strategy. Investors monitoring biotech regulatory catalysts will note this development's potential implications for U.S. market growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.